Business & Growth
Business & Growth
Licensed in Germany, Ready for Europe
HRV Pharma's acquisition of Germany-based Phatebo GmbH provides an established entry into the European pharmaceutical market. With German pharmaceutical wholesale authorisation, good distribution practice systems and an existing global customer base, the acquisition supports HRV's expansion into finished formulations while strengthening its international presence.
Keeping Clinical Trials on Schedule
HRV Pharma's acquisition of Germany-based Phatebo expands its business into clinical trial supply and finished formulations. Phatebo provides investigational, comparator and ancillary medicines through licensed channels, with traceability of origin, batch and expiry to support reliable clinical trial operations.
A New Chapter in Europe
HRV Pharma has entered the European finished formulations market through its acquisition of Germany-based Phatebo. The move gives HRV an established pharmaceutical business with wholesale authorisation, good distribution practice systems and an existing customer base, complementing its global API portfolio.
Two Layers, One Value Chain
HRV Pharma is expanding across two layers of the pharmaceutical value chain through its acquisition of Phatebo GmbH. The combination brings together HRV's global API partner network and Phatebo's licensed European clinical trial supply and pharmaceutical distribution capabilities, while retaining the asset-light business model.
Into Clinical Trial Supply
HRV Pharma has expanded beyond APIs into clinical trial supply through its acquisition of Germany-based Phatebo. The company sources comparator, investigational and ancillary medicines for pharmaceutical companies and CROs worldwide, bringing HRV into a segment where reliability, traceability and timely delivery are essential.
A Foray Into European Markets
HRV Pharma is expanding into European markets through the planned acquisition of Germany-based Phatebo GmbH. The deal provides an entry into finished formulations, clinical trial supply and established pharmaceutical distribution capabilities, including a German wholesale authorisation and long-standing relationships with clinical trial sponsors.
Beyond APIs, Into Finished Formulations
HRV Pharma is expanding beyond APIs into finished formulations through its acquisition of a 100% equity stake in Germany-based Phatebo. The acquisition marks a significant step in HRV's growth, giving the company its first finished formulations business and a licensed operating presence in Germany, while opening new opportunities in the European pharmaceutical market.
Two Bets on Complex Molecules, One Asset Light Model
HRV Pharma is planning a ₹150 crore investment in peptides and high-potency APIs through a dedicated peptide programme and a joint venture focused on specialised oncology molecules. Both initiatives follow the company's asset-light model, retaining intellectual property, regulatory assets and commercial rights while working with specialist manufacturing partners.
Trust Isn't a Feeling. It's a System.
How can a pharmaceutical company maintain quality without owning its manufacturing plants? HRV Pharma builds trust through standardised audits, real-time performance tracking and continuous visibility across 53 partners, helping identify issues before they become shipment or regulatory problems.
Not a Capacity Problem, a Utilisation Problem
When Hari Kiran Chereddi founded HRV Pharma in 2016, he saw an opportunity to address underutilised pharmaceutical manufacturing capacity in India. In this ET Now interview, he explains HRV's asset-light model, its quality assurance systems across 53 sites, and its ambition to reach ₹1,000 crore while remaining debt free.
What Indian Pharma Is Really Buying
Sun Pharma's $11.75 billion acquisition of Organon highlights a broader shift in the Indian pharmaceutical industry. Featuring insights from industry leaders, including HRV Pharma's Hari Kiran Chereddi, BioSpectrum explores the growing importance of brand value, specialty portfolios, biosimilars and access to regulated global markets.
No Factory, ₹400 Crore Revenue: How HRV Made It Happen
How does HRV Pharma generate over ₹400 crore in revenue without owning a manufacturing plant? Discover its asset-light business model, network of 50+ US FDA and EU approved manufacturing partners, and growth to 700+ customers across 55 countries.